-
Something wrong with this record ?
Senescence in hepatic stellate cells as a mechanism of liver fibrosis reversal: a putative synergy between retinoic acid and PPAR-gamma signalings
C. Panebianco, JA. Oben, M. Vinciguerra, V. Pazienza,
Language English Country Italy
Document type Journal Article, Review
NLK
ProQuest Central
from 2002-05-01 to 2018-12-31
Medline Complete (EBSCOhost)
from 2003-05-01 to 1 year ago
Health & Medicine (ProQuest)
from 2002-05-01 to 2018-12-31
- MeSH
- Liver Cirrhosis physiopathology MeSH
- Hepatic Stellate Cells physiology MeSH
- Keratolytic Agents MeSH
- Humans MeSH
- PPAR gamma metabolism MeSH
- Antineoplastic Agents MeSH
- Signal Transduction * MeSH
- Tretinoin metabolism MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
Hepatic stellate cells (HSCs), also known as perisinusoidal cells, are pericytes found in the perisinusoidal space of the liver. HSCs are the major cell type involved in liver fibrosis, which is the formation of scar tissue in response to liver damage. When the liver is damaged, stellate cells can shift into an activated state, characterized by proliferation, contractility and chemotaxis. The activated HSCs secrete collagen scar tissue, which can lead to cirrhosis. Recent studies have shown that in vivo activation of HSCs by fibrogenic agents can eventually lead to senescence of these cells, which would contribute to reversal of fibrosis although it may also favor the insurgence of liver cancer. HSCs in their non-active form store huge amounts of retinoic acid derivatives in lipid droplets, which are progressively depleted upon cell activation in injured liver. Retinoic acid is a metabolite of vitamin A (retinol) that mediates the functions of vitamin A, generally required for growth and development. The precise function of retinoic acid and its alterations in HSCs has yet to be elucidated, and nonetheless in various cell types retinoic acid and its receptors (RAR and RXR) are known to act synergistically with peroxisome proliferator-activated receptor gamma (PPAR-gamma) signaling through the activity of transcriptional heterodimers. Here, we review the recent advancements in the understanding of how retinoic acid signaling modulates the fibrogenic potential of HSCs and proposes a synergistic combined action with PPAR-gamma in the reversal of liver fibrosis.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18025298
- 003
- CZ-PrNML
- 005
- 20180712113934.0
- 007
- ta
- 008
- 180709s2017 it f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s10238-016-0438-x $2 doi
- 035 __
- $a (PubMed)27655446
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a it
- 100 1_
- $a Panebianco, Concetta $u Gastroenterology Unit, IRCCS "Casa Sollievo della Sofferenza" Hospital, Viale dei Cappuccini, 1, San Giovanni Rotondo, FG, Italy.
- 245 10
- $a Senescence in hepatic stellate cells as a mechanism of liver fibrosis reversal: a putative synergy between retinoic acid and PPAR-gamma signalings / $c C. Panebianco, JA. Oben, M. Vinciguerra, V. Pazienza,
- 520 9_
- $a Hepatic stellate cells (HSCs), also known as perisinusoidal cells, are pericytes found in the perisinusoidal space of the liver. HSCs are the major cell type involved in liver fibrosis, which is the formation of scar tissue in response to liver damage. When the liver is damaged, stellate cells can shift into an activated state, characterized by proliferation, contractility and chemotaxis. The activated HSCs secrete collagen scar tissue, which can lead to cirrhosis. Recent studies have shown that in vivo activation of HSCs by fibrogenic agents can eventually lead to senescence of these cells, which would contribute to reversal of fibrosis although it may also favor the insurgence of liver cancer. HSCs in their non-active form store huge amounts of retinoic acid derivatives in lipid droplets, which are progressively depleted upon cell activation in injured liver. Retinoic acid is a metabolite of vitamin A (retinol) that mediates the functions of vitamin A, generally required for growth and development. The precise function of retinoic acid and its alterations in HSCs has yet to be elucidated, and nonetheless in various cell types retinoic acid and its receptors (RAR and RXR) are known to act synergistically with peroxisome proliferator-activated receptor gamma (PPAR-gamma) signaling through the activity of transcriptional heterodimers. Here, we review the recent advancements in the understanding of how retinoic acid signaling modulates the fibrogenic potential of HSCs and proposes a synergistic combined action with PPAR-gamma in the reversal of liver fibrosis.
- 650 _2
- $a protinádorové látky $7 D000970
- 650 _2
- $a jaterní hvězdicovité buňky $x fyziologie $7 D055166
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a keratolytika $7 D007641
- 650 _2
- $a jaterní cirhóza $x patofyziologie $7 D008103
- 650 _2
- $a PPAR gama $x metabolismus $7 D047495
- 650 12
- $a signální transdukce $7 D015398
- 650 _2
- $a tretinoin $x metabolismus $7 D014212
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Oben, Jude A $u Institute for Liver and Digestive Health, Royal Free Hospital, University College London (UCL), London, UK.
- 700 1_
- $a Vinciguerra, Manlio $u Institute for Liver and Digestive Health, Royal Free Hospital, University College London (UCL), London, UK. Center for Translational Medicine (CTM), International Clinical Research Center (ICRC), St. Anne's University Hospital, Brno, Czech Republic. Centro Studi Fegato (CSF)-Liver Research Center, Fondazione Italiana Fegato, Trieste, Italy.
- 700 1_
- $a Pazienza, Valerio $u Gastroenterology Unit, IRCCS "Casa Sollievo della Sofferenza" Hospital, Viale dei Cappuccini, 1, San Giovanni Rotondo, FG, Italy. pazienza_valerio@yahoo.it.
- 773 0_
- $w MED00006222 $t Clinical and experimental medicine $x 1591-9528 $g Roč. 17, č. 3 (2017), s. 269-280
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27655446 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180709 $b ABA008
- 991 __
- $a 20180712114227 $b ABA008
- 999 __
- $a ok $b bmc $g 1317429 $s 1022219
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 17 $c 3 $d 269-280 $e 20160921 $i 1591-9528 $m Clinical and Experimental Medicine $n Clin Exp Med $x MED00006222
- LZP __
- $a Pubmed-20180709